https://www.selleckchem.com/pr....oducts/relacorilant.
66, 95% CI 0.49-0.89), patients with tumour stage III or IV (HR 0.71, 95% CI 0.58-0.88), and those with the least comorbidity (HR 0.71, 95% CI 0.57-0.89). Metformin use may improve survival in gastric adenocarcinoma among diabetes patients. Metformin use may improve survival in gastric adenocarcinoma among diabetes patients. This open-label, Phase 1b/2 study evaluated the highly selective MET inhibitor tepotinib in systemic anticancer treatment (SACT)-naive Asian patients with advanced hepatocellular carcinoma (aHCC) with MET overe
Aimer
Commentaire
Partagez
